PAREXEL ANNOUNCES DATE OF FIRST QUARTER FY 2004 EARNINGS RELEASE AND CONFERENCE CALL
BOSTON, MA, September 23, 2003 — PAREXEL International Corporation (Nasdaq: PRXL) will release First Quarter FY 2004 financial results on Tuesday, October 21, 2003 before the opening of trading. The announcement will be available on PAREXEL’s website at www.parexel.com and on the PR Newswire website at www.prnewswire.com.
Following the release of its results, PAREXEL will host a conference call and live webcast at 10:00 a.m. ET to discuss the results. To access the webcast, visit PAREXEL’s website at www.parexel.com, click on the Investor Relations menu and select “Webcasts”. Double-click the microphone labeled “Q1 Fiscal 2004 PAREXEL International Earnings Conference Call” to begin. This webcast will continue to be accessible for one year following the live broadcast. To participate via telephone, dial (612) 332-0523 and ask to join the PAREXEL quarterly conference call.
PAREXEL is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., develops and offers a portfolio of innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales. The technology portfolio includes web-based portal solutions and tracking tools, Interactive Voice Response Systems (IVRS), Clinical Trial Management Systems (CTMS), electronic diary and investigator database solutions. Perceptive also offers advanced medical diagnostics services to assess rapidly and objectively the safety and efficacy of new drugs, biologics, and medical devices in clinical trials. PAREXEL’s integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 57 locations throughout 36 countries around the world, and has 5,095 employees.